Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2016

View Archived Issues

FF-21101 enters phase I trials for the treatment of solid tumors

Geron announces the initiation of phase II/III study of imetelstat in patients with MDS

Hutchison MediPharma initiates phase I trial of HMPL-523 in hematological malignancies

FDA will not take action on the NDA for Sustol by the planned PDUFA date

EMA grants orphan drug designation to LOXO-101 for treatment of soft tissue sarcoma

Spherium Biomed announces start of phase I trial to evaluate efficacy of SP-12006

NIH analysis identifies three genes that contribute to primary open-angle glaucoma

Roche and BioFocus present novel radiotracers for imaging alpha-synuclein

Novel vaccine against Alzheimer's disease-like characteristics in patients with Down syndrome

Ixico earns new contracts in Alzheimer's disease

EMA approves Samsung Bioepis's biosimilar etanercept Benepali

FDA approves Cosentyx for ankylosing spondylitis and psoriatic arthritis

Crealta acquired by Horizon Pharma

Hinova Pharmaceuticals patents potential treatments for gout

FDA grants priority review to Eisai's lenvatinib for RCC

Pharmacyclics describes BTK inhibitors

Novartis develops sGC activators

Pfizer presents PI3Kalpha inhibitors

Lupin reports development of PI3K inhibitors

Phase III trial of isunakinra in allergic conjunctivitis misses primary endpoint

Specific tracer demonstrates favorable profile in tau pathology

Novel small-molecule Hsp90 inhibitor active in vivo in p53-related tumors

Patient in Bial clinical trial dies, another five patients stable

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...